David Anthony Barda is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of seven patents to his name, Barda's work focuses on developing innovative compounds that target specific cancer-related proteins.

Latest Patents

One of Barda's latest patents involves KRas inhibitors. This invention provides compounds of the formula designed to inhibit KRas G12C, a protein that plays a crucial role in the development of certain cancers. The patent details the compounds of Formula I, where R1, R2, and m are defined, along with pharmaceutically acceptable salts of these compounds. The methods of using these compounds and salts aim to treat patients suffering from cancer, showcasing Barda's commitment to advancing medical science.

Career Highlights

Barda is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to innovative cancer therapies.

Collaborations

Throughout his career, Barda has worked alongside notable colleagues such as Kenneth James Henry, Jr. and Sajan Joseph. These collaborations have played a vital role in the development of his patented inventions and have fostered a productive research environment.

Conclusion

David Anthony Barda's innovative work in the field of cancer treatment through his patents exemplifies the impact of dedicated inventors in the pharmaceutical industry. His contributions continue to pave the way for advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.